Rocket Pharmaceuticals (RCKT) Total Liabilities (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted Total Liabilities of $47.4 million for Q1 2026, down 11.01% sequentially from $53.2 million in Q4 2025, and down 19.62% YoY from $58.9 million in Q1 2025.
Rocket Pharmaceuticals (RCKT) Total Liabilities (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Total Liabilities for 13 years, with the latest figure at $47.4 million in Q1 2026.
- Quarterly Total Liabilities fell 19.62% year-over-year to $47.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.4 million (down 19.62% YoY) and the FY2025 annual result came in at $53.2 million, down 17.43% from the prior year.
- Total Liabilities fell to $47.4 million in Q1 2026 per RCKT's latest filing, from $53.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $73.8 million in Q4 2023 and troughed at $42.5 million in Q1 2022.
- A 5-year average of $57.3 million and a median of $57.9 million in 2024 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 46.87% in 2022, down 55.92% in 2022.
- Over 5 years, Total Liabilities stood at $62.1 million in 2022, then gained by 18.75% to $73.8 million in 2023, then declined by 12.61% to $64.5 million in 2024, then slipped by 17.43% to $53.2 million in 2025, then declined by 11.01% to $47.4 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $47.4 million, $53.2 million, and $54.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Rocket Pharmaceuticals | 380.92 Mn | 380.92 Mn | - | 54.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.27 Mn |
| Mar 31, 2026 | 47.37 Mn |
| Dec 31, 2025 | 53.23 Mn |
| Sep 30, 2025 | 54.36 Mn |
| Jun 30, 2025 | 66.77 Mn |
| Mar 31, 2025 | 58.93 Mn |
| Dec 31, 2024 | 64.47 Mn |
| Sep 30, 2024 | 63.92 Mn |
| Jun 30, 2024 | 61.78 Mn |
| Mar 31, 2024 | 57.94 Mn |
| Dec 31, 2023 | 73.77 Mn |
| Sep 30, 2023 | 57.68 Mn |
| Jun 30, 2023 | 58.81 Mn |
| Mar 31, 2023 | 55.88 Mn |
| Dec 31, 2022 | 62.12 Mn |
| Sep 30, 2022 | 49.95 Mn |
| Jun 30, 2022 | 44.16 Mn |
| Mar 31, 2022 | 42.53 Mn |
| Dec 31, 2021 | 42.30 Mn |
| Sep 30, 2021 | 44.58 Mn |